Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Deferred Taxes (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Deferred Taxes for 4 consecutive years, with $255000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Deferred Taxes fell 79.67% to $255000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.7 million, a 26.97% increase, with the full-year FY2024 number at $2.7 million, up 110.0% from a year prior.
  • Deferred Taxes was $255000.0 for Q3 2025 at Centessa Pharmaceuticals, down from $1.0 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $1.3 million in Q3 2024 to a low of -$23.5 million in Q2 2023.
  • A 4-year average of -$2.0 million and a median of $326500.0 in 2024 define the central range for Deferred Taxes.
  • Peak YoY movement for Deferred Taxes: plummeted 2040.74% in 2023, then surged 367.11% in 2024.
  • Centessa Pharmaceuticals' Deferred Taxes stood at -$2.8 million in 2022, then surged by 94.63% to -$149000.0 in 2023, then soared by 367.11% to $398000.0 in 2024, then crashed by 35.93% to $255000.0 in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Deferred Taxes are $255000.0 (Q3 2025), $1.0 million (Q2 2025), and $995000.0 (Q1 2025).